Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Monday, April 2nd.
Several other brokerages have also commented on ARWR. BidaskClub raised Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 1st. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, February 19th. Cantor Fitzgerald set a $5.00 target price on Arrowhead Pharmaceuticals and gave the company a “neutral” rating in a research note on Monday, February 12th. Jefferies Group began coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, March 27th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, B. Riley began coverage on Arrowhead Pharmaceuticals in a report on Friday, January 5th. They issued a “neutral” rating and a $3.00 price target for the company. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $6.30.
ARWR stock traded up $0.01 during trading on Monday, hitting $6.85. The company had a trading volume of 860,709 shares, compared to its average volume of 1,842,964. Arrowhead Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $8.09. The stock has a market capitalization of $626.60, a PE ratio of -14.77 and a beta of 2.35. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.03.
In related news, CEO Christopher Richard Anzalone sold 300,000 shares of the company’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $7.43, for a total transaction of $2,229,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,194,789 shares of the company’s stock, valued at approximately $16,307,282.27. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kenneth Allen Myszkowski sold 20,000 shares of the company’s stock in a transaction on Tuesday, March 27th. The stock was sold at an average price of $8.00, for a total transaction of $160,000.00. Following the sale, the chief financial officer now directly owns 330,815 shares of the company’s stock, valued at $2,646,520. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 440,000 shares of company stock valued at $3,266,600. Insiders own 4.60% of the company’s stock.
Large investors have recently bought and sold shares of the business. OppenheimerFunds Inc. boosted its position in Arrowhead Pharmaceuticals by 110.0% in the 4th quarter. OppenheimerFunds Inc. now owns 6,300,000 shares of the biotechnology company’s stock valued at $23,184,000 after buying an additional 3,300,000 shares during the last quarter. Vanguard Capital Wealth Advisors bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $119,000. Allianz Asset Management GmbH lifted its position in shares of Arrowhead Pharmaceuticals by 2.2% during the fourth quarter. Allianz Asset Management GmbH now owns 462,105 shares of the biotechnology company’s stock worth $1,701,000 after purchasing an additional 9,985 shares during the last quarter. Quantitative Investment Management LLC bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $203,000. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 10.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after purchasing an additional 16,103 shares during the last quarter. 26.88% of the stock is owned by institutional investors.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.